Isaac Hakim

Isaac Hakim has over 25 years of experience in pre-clinical studies. Isaac began their career in 1993 as a Postdoctoral Fellow at Stanford University. In 1997, they joined Dendreon Corporation as a Scientist II, where they conducted immunotherapy research on prostate cancer and MHC class I processing of OVA protein. In 1999, they moved to Pharmagenesis, Inc. where they held the role of Senior Scientist and Group Leader. Here, they developed in vitro and in vivo assays for hematopoiesis and immune reconstitution and was a member of the drug development team assigned to file INDs. In 2005, they joined Corium International (StrataGent Life Sciences) as a Principle Scientist. Here, they designed, performed, and analyzed in vivo and in vitro preclinical studies to investigate drug delivery systems. In 2008, they moved to Comparative Biosciences, Inc. as a Study Director and Senior Scientist. Here, they directed GLP and non-GLP toxicology, pharmacology and efficacy pre-clinical studies and developed, validated, and implemented established and innovative animal models studies in multiple species. Finally, in 2016, they joined twoXAR as the Director of Pre Clinical Studies.

Isaac Hakim completed a Bachelor of Science in Microbiology, General from The Hebrew University of Jerusalem in 1985. Isaac then earned a Master of Science in Human/Medical Genetics from Tel Aviv University in 1988. In 1993, they obtained a Doctor of Philosophy in Molecular Immunology from Tel Aviv University. Subsequently, Isaac Hakim was a Postdoctoral Fellow in Human Genetics at Stanford University from 1993 to 1997.